Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

Arcturus Therapeutics is viewed positively because its LUNAR platform is now de-risked by KOSTAIVE’s approval, validating its self-amplifying mRNA and lipid delivery technology while also strengthening partnership optionality and future commercialization leverage. The company’s OTC program is showing an encouraging fundamental signal, with updated Ph2 data indicating glutamine and ammonia improvements despite small patient numbers, supporting a higher probability of success from 25% to 35% and a longer-run late 2028 launch framework. Management also has multiple catalysts across ARCT-2601, LUNAR-FLU, and cystic fibrosis, while the Thermo Fisher collaboration provides up to $40M in clinical manufacturing services and another $40M in CRO support, improving execution efficiency.

Arcturus Therapeutics is challenged by greater-than-expected operating expenses and cash burn, which increases reliance on equity issuances and raises dilution risk, especially for a newly commercial company with small revenue. Its pipeline still faces meaningful clinical uncertainty, as ARCT-810 showed activity but had infusion-related reactions, limited interpretability from small studies, no clear biomarker trends, and a slow-enrollment termination, while the need to switch lipid formulations adds further execution risk. Longer development timelines, potential FDA and EMA requirements, and competition from gene-agnostic approaches in urea cycle disorders and other alternative technologies threaten future commercialization and make returns on invested capital harder to achieve.